Buscar en
Clínica e Investigación en Arteriosclerosis (English Edition)
Toda la web
Inicio Clínica e Investigación en Arteriosclerosis (English Edition) Use and persistence of lipid-lowering therapy in patients with severe hyperchole...
Journal Information
Vol. 33. Issue 6.
Pages 308-313 (November - December 2021)
Share
Share
Download PDF
More article options
ePub
Visits
0
Vol. 33. Issue 6.
Pages 308-313 (November - December 2021)
Brief report
Use and persistence of lipid-lowering therapy in patients with severe hypercholesterolemia: A prospective study
Estudio prospectivo sobre uso y persistencia de tratamiento hipolipidemiante en pacientes con hipercolesterolemia severa
Visits
...
María G. Mattaa,
Corresponding author
dra.gabrielamatta@gmail.com

Corresponding author.
, Benjamín Saenza, Laura Schreierb, Agustina Corrala, Agustina Sarobea, Pablo Corrala
a Departamento de Investigación, Facultad de Medicina, Universidad FASTA, Mar del Plata, Argentina
b Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Laboratorio de Lípidos y Aterosclerosis, INFIBIOC-UBA, Buenos Aires, Argentina
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (2)
Table 1. Demographic and clinical characteristics, and lipid levels of patients at the start of the study (2015).
Table 2. Univariate analysis of predictors for cardiovascular events.
Show moreShow less
Abstract
Introduction

Statins are the first line of treatment in patients with severe hypercholesterolemia (SH). However, despite the knowledge regarding its effectiveness and security for preventing cardiovascular diseases, treatment is a major challenge.

Material and methods

A prospective observational study was conducted by telephone survey to determine cardiovascular risk factors, annual monitoring, statins use and persistence and new-onset cardiovascular events (CVE) after 5 years in patients with HS including in a programme for detection of familial hypercholesterolemia.

Results

115 participants were analysed, the median age was 56 ± 10 being 74% females. 63.4% of women and 43% of men had been correctly controlled in the last year. Patients on lipid lowering drugs stratified by sex was 38.8% in women and 26.7% in men, however, only 22 participants (31.8%) were persistence with statins since 2015.Overall, 48% of the patients presented a CVE and 3.4% died. Multivariate analysis did not reveal predictors for CVE.

Conclusions

In our population with SH we found a high risk to present a CVE and a dramatic low use and persistence with the treatment.

Keywords:
Lipid-lowering therapy
Adherence
Persistence hypercholesterolemia
Cardiovascular disease
Resumen
Introducción

Las estatinas son la primera línea de tratamiento en pacientes con hipercolesterolemia severa (HS). A pesar de la evidencia disponible sobre su eficacia y seguridad para prevenir eventos cardiovasculares, el correcto tratamiento sigue siendo un desafío.

Materiales y métodos

Estudio observacional prospectivo diseñado para determinar mediante entrevista telefónica la presencia de factores de riesgo, seguimiento clínico anual, persistencia/uso de estatinas y aparición de nuevos eventos cardiovasculares (ECV) después de 5 años, en pacientes con HS incluidos en un programa de Detección de Hipercolesterolemia Familiar.

Resultados

Se evaluaron 115 participantes, la edad media fue de 56 ± 10 siendo el 74% mujeres. El 63.4% de las mujeres y el 43% de los hombres refirió estar bajo seguimiento y control clínico en el último año. El 38.8% de las mujeres recibió estatinas versus el 26.7% de los hombres, y, solo 22 participantes (31.8%) fueron persistentes con el tratamiento desde 2015. El 15.5% de los participantes presentó un ECV no fatal y el 3.4% fatal. En el análisis multivariado no se detectaron predictores para presentar un ECV.

Conclusiones

En nuestra población con HS encontramos un alto riesgo de presentar un ECV y una dramática baja tasa de uso y persistencia al tratamiento con estatinas.

Palabras claves:
Tratamiento hipolipemiante
Adherencia
Persistencia, Hipercolesterolemia
Enfermedad cardiovascular

Article

These are the options to access the full texts of the publication Clínica e Investigación en Arteriosclerosis (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Clínica e Investigación en Arteriosclerosis (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos